WallStSmart

Abbott Laboratories (ABT)vsBioventus Inc (BVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 7906% more annual revenue ($46.59B vs $581.85M). ABT leads profitability with a 11.7% profit margin vs 9.4%. BVS appears more attractively valued with a PEG of 1.53. BVS earns a higher WallStSmart Score of 62/100 (C+).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

BVS

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 5.7Quality: 4.5
Piotroski: 5/9Altman Z: 0.90
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-37.5%)

Margin of Safety

-37.5%

Fair Value

$74.13

Current Price

$101.95

$27.82 premium

UndervaluedFair: $74.13Overvalued

Intrinsic value data unavailable for BVS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$176.41B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.09B8/10

Generating 2.1B in free cash flow

BVS3 strengths · Avg: 9.0/10
EPS GrowthGrowth
327.3%10/10

Earnings expanding 327.3% YoY

Return on EquityProfitability
23.9%9/10

Every $100 of equity generates 24 in profit

P/E RatioValuation
16.6x8/10

Attractively priced relative to earnings

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

BVS4 concerns · Avg: 3.5/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

Market CapQuality
$886.60M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.163/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : BVS

The strongest argument for BVS centers on EPS Growth, Return on Equity, P/E Ratio.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : BVS

The primary concerns for BVS are PEG Ratio, Revenue Growth, Market Cap.

Key Dynamics to Monitor

BVS carries more volatility with a beta of 0.65 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BVS scores higher overall (62/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Bioventus Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.

Want to dig deeper into these stocks?